Journal Article

Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada

Hew, Huong, Hamilton, Robert J, Fernandes, Ricardo, Morgan, Scott C, Noonan, Krista L, Saad, Fred, Chan, Katherine F. Y, Cagiannos, Ilinas, Shayegan, Bobby, Niazi, Tamim, Gotto, Geoffrey T, Park-Wyllie, Laura, Roy, Soumyajit, Basappa, Naveen S, Malone, Shawn, Wallis, Christopher J. D, Ferrario, Cristiano, Hotte, Sebastien J

2023

Overview

BackgroundThe adoption of docetaxel for systemic treatment of metastatic prostate cancer (PCa), in both castration-sensitive (mCSPC) and castration-resistant (mCRPC) settings, is poorly understood. This study examined the real-world utilization of docetaxel in these patients and their outcomes.MethodsA retrospective population-based study used administrative data from Ontario, Canada, to identify men aged ≥66 years who were diagnosed with de novo mCSPC or mCRPC between 2014 and 2019 and received docetaxel. The study assessed treatment tolerability and toxicity, and survival in both cohorts. Descriptive and comparative statistical analysis were conducted.ResultsThe study identified 11.2% (399/3556) and 13.2% (203/1534) patients diagnosed with de novo mCSPC and with mCRPC who received docetaxel respectively. The median age in both cohorts was 72 years (IQR: 68–76). Overall, 43.9% (n = 175) patients with de novo mCSPC and 52.1% (n = 85) with mCRPC completed ≥6 cycles of docetaxel. Over two-fifth also needed dose adjustments in both cohorts. Hospitalization or emergency department visit for febrile neutropenia were noted in 15.8% (n = 63) of de novo mCSPC patients and similarly in 19% (n = 31) of mCRPC cohort. The median survival of PCa patients who completed ≥6 cycles of docetaxel was significantly longer relative to those who completed <4 cycles: 32.7 vs. 23.5 months (p < 0.001) for mCSPC and 20.5 vs. 10.7 (p = 0.012) for mCRPC respectively.ConclusionsIn this population-based study of elderly patients with metastatic PCa, treatment with docetaxel was associated with poor tolerability and higher toxicity compared with clinical trials. Receipt of limited cycles and reduced overall dose of docetaxel were associated with inferior overall survival.

• Publisher: Nature Publishing Group
• Subject: Aging / Castration / Chemotherapy / Clinical outcomes / Clinical trials / Cohort analysis / Data analysis / Drug dosages / Electronic health records / Emergency medical care / Emergency medical services / Health care / Metastases / Metastasis / Neutropenia / Older people / Patients / Population studies / Population-based studies / Prostate cancer / Statistical analysis / Survival / Survival analysis / Toxicity